Pharmaceuticals
News Category
VERAXA Biotech Advances Lead BiTAC T-Cell Engager Program with Cell Line Development Partnership
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program by partnering with ATUM, marking a key milestone toward I...
Sustained Release Polymers Market Set to Reach USD 7.8 Billion by 2036, Driven by Chronic Disease Management and Drug Delivery Innovation
The global sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by...
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026
VERAXA Biotech AG reports progress in its BiTAC platform with four T-cell engager programs targeting solid tumors, plans to prioritize BiTAC developme...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM, aiming to advance a novel ...
Antibody Therapeutics Sector Deal Activity Highlights Value of Early-Stage Innovation, VERAXA Biotech Positioned to Benefit
The article discusses sustained deal activity in antibody-drug conjugates (ADCs) and T-cell engagers, noting that pharmaceutical companies are committ...
Ace Therapeutics Launches Comprehensive Preclinical Analgesic Drug Development Platform
Ace Therapeutics announces a full-spectrum preclinical research platform for analgesic drug development, offering diverse in vivo pain models and end-...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to address margin pressure from regulatory price adju...
Helus Pharma Reports Fiscal 2026 Results, Highlights Phase 3 Progress for Major Depressive Disorder Treatment
Helus Pharma announced fiscal 2026 financial results and provided updates on its clinical pipeline, including Phase 3 progress for HLP003 in major dep...
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility and an integrated contrast drug ...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics has repaid its $60 million revolving credit facility used to acquire Paladin, funded by strong operational cash flow, maintaining ...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is evaluating three U.S. sites for its first fully domestic, vertically integrated iodine and barium contrast media manufactu...
Earth Science Tech Inc. (ETST) Strengthens Position at Intersection of Telemedicine, Pharmacy, and Healthcare Services
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emphasizing...
Voyageur Pharmaceuticals Submits Multi-Year Exploration Permit for Frances Creek Barite Project, Advancing Toward Feasibility and North American API Supply
Voyageur Pharmaceuticals has applied for a five-year advanced exploration permit at its Frances Creek barite project in British Columbia, including a ...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for Barium Contrast FDA Licensing and Iodine Project Development
Voyageur Pharmaceuticals has closed a non-brokered private placement raising $5,005,278.32 to fund FDA licensing for its barium contrast products, reg...
Kairos Pharma Pipeline Expansion and Clinical Milestones Highlighted in Mid-Year Update
Kairos Pharma announced plans to acquire rights to a Phase 1-ready c-MET inhibitor, advance existing clinical trials, and secure non-dilutive funding,...
Quantum BioPharma Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
Quantum BioPharma’s lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd(TM) were featured on a p...
Quantum BioPharma Advances Differentiated MS Program and Diversified Pipeline
Quantum BioPharma's clinical-stage multiple sclerosis program targeting demyelination and diversified portfolio spanning therapeutics and consumer wel...
Redwood AI Corp. Achieves DTC Eligibility and Engages IBN for Investor Awareness
Redwood AI Corp.'s DTC eligibility simplifies U.S. trading and its engagement with IBN aims to boost market visibility through a comprehensive investo...
Carmed Pharmaceuticals' CityBiz Feature Highlights U.S. Expansion and Research-Driven Approach
Carmed Pharmaceuticals, a Turkey-based company specializing in carvacrol-based formulations, is expanding into the U.S. market, as highlighted in a Ci...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered Antibody Discovery
Sino Biological's new XPressMAX™ kit enables ultra-fast, cell-free protein synthesis in 3 hours, integrating with AI-driven high-throughput screening ...
NanoViricides Advances NV-387 Toward Phase II Trials for MPox and Other Viral Diseases
NanoViricides reported progress in developing its broad-spectrum antiviral candidate NV-387, including regulatory approval for a Phase II MPox trial i...
NanoViricides Prices $2 Million Registered Direct Offering
NanoViricides has announced a $2 million registered direct offering to an institutional investor, providing capital for its clinical-stage antiviral d...
Lantern Pharma Closes $4.4 Million Registered Direct Offering to Advance AI-Driven Precision Oncology Pipeline
Lantern Pharma raised $4.4 million through a registered direct offering and concurrent private placement, providing capital to advance its precision o...
Tonix Pharmaceuticals to Present at Two Investor Conferences in May
Tonix Pharmaceuticals (NASDAQ: TNXP) will present at the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Annual Virtual Healthcare Confe...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma's expansion of its predictBBB platform into a Large Quantitative Model enhances drug discovery by providing real-time molecular intelli...
LIXTE Biotechnology Holdings Advances LB-100 as Novel Cancer Treatment Approach
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, enhances chemotherapy and immunotherapy effectiveness by disrupting DNA repair in cance...
Soligenix's Platform Approach Highlights Efficiency in Drug Development for Multiple Indications
Soligenix leverages synthetic hypericin across CTCL and psoriasis, exemplifying how platform science streamlines development and expands clinical impa...
PolyPeptide Shareholders Approve All Board Proposals at 2026 Annual General Meeting
PolyPeptide Group AG's shareholders voted overwhelmingly in favor of all board proposals at the 2026 AGM, including re-election of directors and appro...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Detailing Transformational Year With Clinical Progress and Strategic Acquisition
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Form 10-K, highlighting leadership changes, clinical advancement of LB-100, acquisition of ...
LIXTE Biotechnology Holds World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
LIXTE Biotechnology's LB-100 is the only clinical-stage PP2A inhibitor, potentially enhancing cancer therapies by sensitizing tumors to immunotherapy ...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates Stephen Fry, former Eli Lilly executive, to its board to leverage his expertise in organizational transformation and performance cultu...
Voyageur Provides Update on Barium and Iodine Contrast Media Projects, Targeting North American Production
Voyageur Pharmaceuticals advances its vertically integrated barium and iodine contrast media projects with feasibility studies and FDA submissions, ai...
Soligenix Secures Key European Milestone for Dusquetide Development
Soligenix received a positive opinion from the EMA for orphan drug designation of dusquetide for Behcet's disease, unlocking incentives that may accel...
NETHERTON NOW Campaign Surpasses 2 Million Video Views, Amplifying Voices of Netherton Syndrome Community on Rare Disease Day
Quoin Pharmaceuticals' NETHERTON NOW awareness campaign has generated 2 million video views and 24 million impressions, highlighting the growing globa...
Oncotelic Therapeutics Featured in BioMedWire Editorial Highlighting Late-Stage Biotech M&A Trends
Oncotelic Therapeutics' inclusion in a BioMedWire editorial underscores the increasing M&A focus on de-risked, late-stage oncology and CNS assets, pos...
Helus Pharma Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Helus Pharma announced that Phase 2a trial results for SPL026, published in Nature Medicine, showed statistically significant reduction in depressive ...